In May 2017, Bioverativ signed a definitive agreement to acquire privately-held rare disease developer True North Therapeutics for up to $825 million.

As part of the acquisition, Bioverativ obtained rights to True North’s lead candidate, TNT009, a first-in-class monoclonal antibody in development to treat cold agglutinin disease (CAD), a rare and chronic hemolytic condition that often leads to severe anemia, requiring numerous transfusions, and can result in life-threatening thrombotic events.